{"id":10300,"date":"2026-09-09T13:10:09","date_gmt":"2026-09-09T13:10:09","guid":{"rendered":"https:\/\/europepharmacy.eu\/?post_type=product&#038;p=10300"},"modified":"2026-09-17T09:51:36","modified_gmt":"2026-09-17T09:51:36","slug":"retatrutide-10mg","status":"publish","type":"product","link":"https:\/\/europepharmacy.eu\/de\/shop\/retatrutide-10mg\/","title":{"rendered":"Retatrutide 10MG"},"content":{"rendered":"<h1><\/h1>\n<h1><a href=\"http:\/\/google.com\">Retatrutide 10MG<\/a><\/h1>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<p class=\"mb-2 last:mb-0\"><a href=\"https:\/\/oroviabiolab.com\/\">Retatrutide<\/a> uniquely activates\u00a0<strong>GLP-1, GIP, and glucagon receptors<\/strong>\u00a0simultaneously, creating synergistic effects:<\/p>\n<ul>\n<li><strong>GLP-1<\/strong>: Reduces hunger via brain signaling; delays stomach emptying.<\/li>\n<li><strong>GIP<\/strong>: Boosts insulin post-meal; improves fat browning (energy-burning).<\/li>\n<li><strong>Glucagon<\/strong>: Increases thermogenesis (calorie burn) and reduces liver fat without raising blood sugar excessively.<\/li>\n<\/ul>\n<p class=\"mb-2 last:mb-0\"><strong>Key Advantage at 10 mg<\/strong>: Highest receptor occupancy leads to maximal glucagon-driven fat oxidation. Preclinical data (Nature Medicine, 2022) shows 30\u201350% greater energy expenditure vs. dual-agonists.<\/p>\n<h4><strong>Detailed Clinical Data for 10 mg Dose<\/strong><\/h4>\n<p class=\"mb-2 last:mb-0\">From pivotal\u00a0<strong>Phase 2 trials<\/strong>\u00a0(published NEJM June 2023; n=338 obese\/non-diabetic adults):<\/p>\n<\/div>\n<div class=\"overflow-x-auto my-4\">\n<table class=\"markdown-table\">\n<thead>\n<tr>\n<th>Dosis<\/th>\n<th>% Body Weight Loss (48 weeks)<\/th>\n<th>% with \u226515% Loss<\/th>\n<th>HbA1c Change (T2D trial)<\/th>\n<th>Key Metabolic Improvements<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>10 mg<\/td>\n<td>-17.5%** (obesity);\u00a0<strong>-16.9%<\/strong>\u00a0(T2D)<\/td>\n<td>76\u201381%<\/td>\n<td>-1.8%<\/td>\n<td>\u2193 Liver fat 82%; \u2193 Triglycerides 30%; \u2193 BP 6\u20138 mmHg<\/td>\n<\/tr>\n<tr>\n<td>4 mg (comparative)<\/td>\n<td>-12.9%<\/td>\n<td>64%<\/td>\n<td>-1.4%<\/td>\n<td>Moderate<\/td>\n<\/tr>\n<tr>\n<td>Placebo<\/td>\n<td>-1.6%<\/td>\n<td>27%<\/td>\n<td>-0.3%<\/td>\n<td>Minimal<\/td>\n<\/tr>\n<tr>\n<td>Tirzepatide 15 mg** (benchmark)<\/td>\n<td>~20% (SURMOUNT-1)<\/td>\n<td>57%<\/td>\n<td>-2.3%<\/td>\n<td>Similar but less liver fat reduction<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<ul>\n<li><strong>Phase 3 (TRIUMPH-1\/2, ongoing)<\/strong>: Targeting 88 weeks; interim data suggests\u00a0<strong>&gt;25% loss<\/strong>\u00a0at 10\u201312 mg.<\/li>\n<li><strong>72-week extension<\/strong>: 10 mg group maintained\u00a0<strong>-24.2%<\/strong>\u00a0loss; 90% kept \u226515% off.<\/li>\n<\/ul>\n<p class=\"mb-2 last:mb-0\"><strong>Subgroup Benefits<\/strong>:<\/p>\n<ul>\n<li><strong>Liver Disease<\/strong>: 80\u201390% NAFLD resolution (vs. 20% placebo).<\/li>\n<li><strong>Heart Health<\/strong>: \u2193 Waist circumference 18 cm; improved insulin sensitivity.<\/li>\n<\/ul>\n<h4><strong>Administration and Titration Protocol (Trial Standard)<\/strong><\/h4>\n<p class=\"mb-2 last:mb-0\">Weekly SC injection (abdomen\/thigh\/arm).\u00a0<strong>Slow titration<\/strong>\u00a0minimizes GI side effects:<\/p>\n<\/div>\n<div class=\"overflow-x-auto my-4\">\n<table class=\"markdown-table\">\n<thead>\n<tr>\n<th>Woche<\/th>\n<th>Dose (mg)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1\u20134<\/td>\n<td>2.5<\/td>\n<\/tr>\n<tr>\n<td>5\u20138<\/td>\n<td>5<\/td>\n<\/tr>\n<tr>\n<td>9+<\/td>\n<td>10** (maintenance)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<ul>\n<li><strong>Halbwertszeit<\/strong>: ~6 days (steady-state by week 4).<\/li>\n<li><strong>Lagerung<\/strong>: Refrigerate; stable 21 days room temp.<\/li>\n<\/ul>\n<h4><strong>Side Effects Profile (10 mg Specific)<\/strong><\/h4>\n<p class=\"mb-2 last:mb-0\">Mostly mild-moderate, peaking during titration (resolve in 80% by week 12).<\/p>\n<\/div>\n<div class=\"overflow-x-auto my-4\">\n<table class=\"markdown-table\">\n<thead>\n<tr>\n<th>Adverse Event<\/th>\n<th>Incidence (10 mg)<\/th>\n<th>Severity\/Management<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Brechreiz<\/td>\n<td>58%<\/td>\n<td>Mild; antiemetics (ondansetron)<\/td>\n<\/tr>\n<tr>\n<td>Vomiting<\/td>\n<td>32%<\/td>\n<td>Dose-hold if severe<\/td>\n<\/tr>\n<tr>\n<td>Durchfall<\/td>\n<td>25%<\/td>\n<td>Hydration, loperamide<\/td>\n<\/tr>\n<tr>\n<td>Increased HR** (+10 bpm)<\/td>\n<td>20%<\/td>\n<td>Monitor; resolves post-dose<\/td>\n<\/tr>\n<tr>\n<td>Serious (rare &lt;2%)<\/td>\n<td>Gallbladder (1.5%), hypoglycemia (T2D)<\/td>\n<td>Stop if pancreatitis suspected<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<p class=\"mb-2 last:mb-0\"><strong>Kontraindikationen<\/strong>: Personal\/family medullary thyroid cancer history, MEN2, severe GI disease.<\/p>\n<h4><strong>Unofficial 10 mg Products (Compounded\/Research Chem)<\/strong><\/h4>\n<ul>\n<li><strong>Common Forms<\/strong>: 10 mg vials (lyophilized powder; reconstitute with bacteriostatic water). ~$200\u2013500\/vial (10\u201320 doses) from sites like Peptide Sciences or Chinese suppliers.<\/li>\n<li><strong>Quality Issues<\/strong>\u00a0(Verified by 3rd-party labs like Colmaric Analyticals, 2024):<\/li>\n<\/ul>\n<\/div>\n<div class=\"overflow-x-auto my-4\">\n<table class=\"markdown-table\">\n<thead>\n<tr>\n<th>Issue<\/th>\n<th>Prevalence<\/th>\n<th>Risiko<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>&lt;80% Purity<\/td>\n<td>40% of samples<\/td>\n<td>Reduced efficacy\/toxins<\/td>\n<\/tr>\n<tr>\n<td>Bacterial Contamination<\/td>\n<td>15%<\/td>\n<td>Infections<\/td>\n<\/tr>\n<tr>\n<td>Incorrect Labeling (e.g., actually tirzepatide)<\/td>\n<td>10%<\/td>\n<td>Unexpected effects<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<ul>\n<li><strong>DIY Dosing Risks<\/strong>: Overdose \u2192 severe dehydration; underdose \u2192 no results. No sterility guarantees.<\/li>\n<\/ul>\n<h4><strong>Comparisons and Future Outlook<\/strong><\/h4>\n<\/div>\n<div class=\"overflow-x-auto my-4\">\n<table class=\"markdown-table\">\n<thead>\n<tr>\n<th>Arzneimittel<\/th>\n<th>Max Dosis<\/th>\n<th>Max Weight Loss<\/th>\n<th>Cost (US, approved)<\/th>\n<th>Approval Status<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Retatrutide 10 mg<\/td>\n<td>10\u201312 mg<\/td>\n<td>24\u201330% (proj.)<\/td>\n<td>TBD (~$1k\/month?)<\/td>\n<td>Phase 3 (2026?)<\/td>\n<\/tr>\n<tr>\n<td>Tirzepatide<\/td>\n<td>15 mg<\/td>\n<td>22%<\/td>\n<td>$1,000\/month<\/td>\n<td>Approved<\/td>\n<\/tr>\n<tr>\n<td>Semaglutide<\/td>\n<td>2,4 mg<\/td>\n<td>15\u201320%<\/td>\n<td>$1,300\/month<\/td>\n<td>Approved<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<p class=\"mb-2 last:mb-0\"><strong>Projections<\/strong>: Lilly aims for obesity + T2D + NASH indications. Patent protection to 2036+.<\/p>\n<p class=\"mb-2 last:mb-0\"><strong>Final Advice<\/strong>: Experimental\u2014pursue via clinical trials (e.g., Lilly&#8217;s site) or wait for approval. Track via\u00a0<a>Lilly Pipeline<\/a>\u00a0or PubMed. Physician oversight essential for any use.<\/p>\n<p class=\"mb-2 last:mb-0\">Sources: NEJM (2023), Lancet (2024 Phase 3 updates), FDA trial registry, independent lab reports. Updated Oct 2024.<\/p>\n<h1><a href=\"http:\/\/google.com\"><img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone size-medium wp-image-14741\" src=\"https:\/\/oroviabiolab.com\/wp-content\/uploads\/2026\/03\/photo_5920301857500761448_y-200x300.jpg\" alt=\"\" width=\"200\" height=\"300\" \/><\/a><\/h1>\n<\/div>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div>","protected":false},"excerpt":{"rendered":"<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<ul>\n<li><strong>GLP-1<\/strong>\u00a0(glucagon-like peptide-1): Suppresses appetite and slows gastric emptying.<\/li>\n<li><strong>GIP<\/strong>\u00a0(glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and fat metabolism.<\/li>\n<li><strong>Glucagon<\/strong>: Promotes energy expenditure and liver fat reduction.<\/li>\n<\/ul>\n<p class=\"mb-2 last:mb-0\">It&#8217;s primarily studied for\u00a0<strong>Adipositas<\/strong>\u00a0und\u00a0<strong>type 2 diabetes<\/strong>, showing superior weight loss compared to single- or dual-agonists like semaglutide (Ozempic\/Wegovy) or tirzepatide (Mounjaro\/Zepbound) in clinical trials.<\/p>\n<p class=\"mb-2 last:mb-0\"><strong>Status<\/strong>: Not FDA-approved (as of October 2024). It&#8217;s in Phase 3 trials (e.g., TRIUMPH studies), with potential approval expected in 2026\u20132027.<\/p>\n<h3>10 mg Dosage Context<\/h3>\n<ul>\n<li><strong>Clinical Trial Dosing<\/strong>: Retatrutide is administered\u00a0<strong>weekly via subcutaneous injection<\/strong>. The 10 mg dose is a\u00a0<strong>high-end maintenance dose<\/strong>\u00a0tested in trials:<\/li>\n<\/ul>\n<\/div>\n<div class=\"overflow-x-auto my-4\">\n<table class=\"markdown-table\">\n<thead>\n<tr>\n<th>Phase\/Trial<\/th>\n<th>Anfangsdosis<\/th>\n<th>Titration<\/th>\n<th>Max Dosis<\/th>\n<th>Weight Loss (at 48\u201372 weeks)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Phase 2 (Obesity)<\/td>\n<td>1 mg<\/td>\n<td>Gradual increase every 4 weeks<\/td>\n<td>10 mg** or 12 mg<\/td>\n<td>Up to\u00a0<strong>24.2%<\/strong>\u00a0body weight loss (vs. 2.1% placebo)<\/td>\n<\/tr>\n<tr>\n<td>Phase 2 (T2D)<\/td>\n<td>0.5 mg<\/td>\n<td>Gradual<\/td>\n<td>10 mg<\/td>\n<td>~17% weight loss + A1C reduction<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<ul>\n<li><strong>Hinweise<\/strong>:\n<ul>\n<li>Phase 2 results (NEJM, 2023): At 10\u201312 mg, participants lost 17\u201324% body weight over 48 weeks, with improvements in liver fat, cardiometabolic markers (e.g., blood pressure, lipids), and glycemic control.<\/li>\n<li>Superior to tirzepatide&#8217;s ~20% loss in head-to-head potential (Phase 3 ongoing).<\/li>\n<li>Side effects: Mostly GI (nausea, vomiting, diarrhea; 50\u201370% incidence, dose-dependent). Rare: gallbladder issues, elevated heart rate.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h3>Availability and Warnings<\/h3>\n<ul>\n<li><strong>Not Commercially Available<\/strong>: No official 10 mg vials\/pens exist. &#8220;Retatrutide 10 mg&#8221; products online are typically\u00a0<strong>unregulated research chemicals<\/strong>\u00a0from compounding pharmacies or overseas labs (e.g., China). Purity is unverified\u2014risk of contamination, underdosing, or fakes.<\/li>\n<li><strong>Risks of Unofficial Use<\/strong>:<\/li>\n<\/ul>\n<\/div>\n<div class=\"overflow-x-auto my-4\">\n<table class=\"markdown-table\">\n<thead>\n<tr>\n<th>Risiko<\/th>\n<th>Details<\/th>\n<th>Hinweise<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Sicherheit<\/td>\n<td>No long-term human data; potential for severe GI issues, pancreatitis, or thyroid tumors (GLP-1 class risk).<\/td>\n<td>FDA warnings on compounded semaglutide\/tirzepatide analogs.<\/td>\n<\/tr>\n<tr>\n<td>Rechtm\u00e4\u00dfigkeit<\/td>\n<td>Illegal to buy\/sell without prescription in most countries (e.g., US Schedule not yet set, but compounding restricted).<\/td>\n<td>DEA\/FDA crackdowns on GLP-1 knockoffs.<\/td>\n<\/tr>\n<tr>\n<td>Wirksamkeit<\/td>\n<td>Variable potency; lab tests show some &#8220;retatrutide&#8221; as low as 50% pure.<\/td>\n<td>Independent testing (e.g., Janoshik Analytics).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"prose break-words dark:prose-invert prose-p:leading-relaxed prose-pre:p-0 fix-max-with-100 prose-p:!mt-0\">\n<p class=\"mb-2 last:mb-0\"><strong>Empfehlung<\/strong>: Do not self-administer. Consult a doctor for supervised trials or approved alternatives (e.g., tirzepatide). Off-label use lacks safety data\u2014monitor via bloodwork if proceeding under medical guidance.<\/p>\n<\/div>","protected":false},"featured_media":10362,"comment_status":"open","ping_status":"closed","template":"","meta":{"postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""}},"product_brand":[],"product_cat":[793],"product_tag":[796],"class_list":["post-10300","product","type-product","status-publish","has-post-thumbnail","product_cat-accessories","product_tag-retatrutide-10mg","instock","shipping-taxable","purchasable","product-type-simple"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Retatrutide 10MG<\/title>\n<meta name=\"description\" content=\"GLP-1\u00a0(glucagon-like peptide-1): Suppresses appetite and slows gastric emptying.  GIP\u00a0(glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and fat metabolism.  Glucagon: Promotes energy expenditure and liver fat reduction.  It&#039;s primarily studied for\u00a0obesity\u00a0and\u00a0type 2 diabetes, showing superior weight loss compared to single- or dual-agonists like semaglutide (Ozempic\/Wegovy) or tirzepatide (Mounjaro\/Zepbound) in clinical trials. Status: Not FDA-approved (as of October 2024). It&#039;s in Phase 3 trials (e.g., TRIUMPH studies), with potential approval expected in 2026\u20132027.  10 mg Dosage Context   Clinical Trial Dosing: Retatrutide is administered\u00a0weekly via subcutaneous injection. The 10 mg dose is a\u00a0high-end maintenance dose\u00a0tested in trials:       Phase\/Trial Starting Dose Titration Max Dose Weight Loss (at 48\u201372 weeks)     Phase 2 (Obesity) 1 mg Gradual increase every 4 weeks 10 mg** or 12 mg Up to\u00a024.2%\u00a0body weight loss (vs. 2.1% placebo)   Phase 2 (T2D) 0.5 mg Gradual 10 mg ~17% weight loss + A1C reduction        Evidence:   Phase 2 results (NEJM, 2023): At 10\u201312 mg, participants lost 17\u201324% body weight over 48 weeks, with improvements in liver fat, cardiometabolic markers (e.g., blood pressure, lipids), and glycemic control.  Superior to tirzepatide&#039;s ~20% loss in head-to-head potential (Phase 3 ongoing).  Side effects: Mostly GI (nausea, vomiting, diarrhea; 50\u201370% incidence, dose-dependent). Rare: gallbladder issues, elevated heart rate.    Availability and Warnings   Not Commercially Available: No official 10 mg vials\/pens exist. &quot;Retatrutide 10 mg&quot; products online are typically\u00a0unregulated research chemicals\u00a0from compounding pharmacies or overseas labs (e.g., China). Purity is unverified\u2014risk of contamination, underdosing, or fakes.  Risks of Unofficial Use:       Risk Details Evidence     Safety No long-term human data; potential for severe GI issues, pancreatitis, or thyroid tumors (GLP-1 class risk). FDA warnings on compounded semaglutide\/tirzepatide analogs.   Legality Illegal to buy\/sell without prescription in most countries (e.g., US Schedule not yet set, but compounding restricted). DEA\/FDA crackdowns on GLP-1 knockoffs.   Efficacy Variable potency; lab tests show some &quot;retatrutide&quot; as low as 50% pure. Independent testing (e.g., Janoshik Analytics).      Recommendation: Do not self-administer. Consult a doctor for supervised trials or approved alternatives (e.g., tirzepatide). Off-label use lacks safety data\u2014monitor via bloodwork if proceeding under medical guidance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/europepharmacy.eu\/de\/shop\/retatrutide-10mg\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide 10MG\" \/>\n<meta property=\"og:description\" content=\"GLP-1\u00a0(glucagon-like peptide-1): Suppresses appetite and slows gastric emptying.  GIP\u00a0(glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and fat metabolism.  Glucagon: Promotes energy expenditure and liver fat reduction.  It&#039;s primarily studied for\u00a0obesity\u00a0and\u00a0type 2 diabetes, showing superior weight loss compared to single- or dual-agonists like semaglutide (Ozempic\/Wegovy) or tirzepatide (Mounjaro\/Zepbound) in clinical trials. Status: Not FDA-approved (as of October 2024). It&#039;s in Phase 3 trials (e.g., TRIUMPH studies), with potential approval expected in 2026\u20132027.  10 mg Dosage Context   Clinical Trial Dosing: Retatrutide is administered\u00a0weekly via subcutaneous injection. The 10 mg dose is a\u00a0high-end maintenance dose\u00a0tested in trials:       Phase\/Trial Starting Dose Titration Max Dose Weight Loss (at 48\u201372 weeks)     Phase 2 (Obesity) 1 mg Gradual increase every 4 weeks 10 mg** or 12 mg Up to\u00a024.2%\u00a0body weight loss (vs. 2.1% placebo)   Phase 2 (T2D) 0.5 mg Gradual 10 mg ~17% weight loss + A1C reduction        Evidence:   Phase 2 results (NEJM, 2023): At 10\u201312 mg, participants lost 17\u201324% body weight over 48 weeks, with improvements in liver fat, cardiometabolic markers (e.g., blood pressure, lipids), and glycemic control.  Superior to tirzepatide&#039;s ~20% loss in head-to-head potential (Phase 3 ongoing).  Side effects: Mostly GI (nausea, vomiting, diarrhea; 50\u201370% incidence, dose-dependent). Rare: gallbladder issues, elevated heart rate.    Availability and Warnings   Not Commercially Available: No official 10 mg vials\/pens exist. &quot;Retatrutide 10 mg&quot; products online are typically\u00a0unregulated research chemicals\u00a0from compounding pharmacies or overseas labs (e.g., China). Purity is unverified\u2014risk of contamination, underdosing, or fakes.  Risks of Unofficial Use:       Risk Details Evidence     Safety No long-term human data; potential for severe GI issues, pancreatitis, or thyroid tumors (GLP-1 class risk). FDA warnings on compounded semaglutide\/tirzepatide analogs.   Legality Illegal to buy\/sell without prescription in most countries (e.g., US Schedule not yet set, but compounding restricted). DEA\/FDA crackdowns on GLP-1 knockoffs.   Efficacy Variable potency; lab tests show some &quot;retatrutide&quot; as low as 50% pure. Independent testing (e.g., Janoshik Analytics).      Recommendation: Do not self-administer. Consult a doctor for supervised trials or approved alternatives (e.g., tirzepatide). Off-label use lacks safety data\u2014monitor via bloodwork if proceeding under medical guidance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/europepharmacy.eu\/de\/shop\/retatrutide-10mg\/\" \/>\n<meta property=\"og:site_name\" content=\"European Pharmacy\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-17T09:51:36+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/retatrutide-10mg\\\/\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/retatrutide-10mg\\\/\",\"name\":\"Retatrutide 10MG\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/retatrutide-10mg\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/retatrutide-10mg\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/photo_5051033548038540504_x.jpg\",\"datePublished\":\"2026-09-09T13:10:09+00:00\",\"dateModified\":\"2026-09-17T09:51:36+00:00\",\"description\":\"GLP-1\u00a0(glucagon-like peptide-1): Suppresses appetite and slows gastric emptying. GIP\u00a0(glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and fat metabolism. Glucagon: Promotes energy expenditure and liver fat reduction. It's primarily studied for\u00a0obesity\u00a0and\u00a0type 2 diabetes, showing superior weight loss compared to single- or dual-agonists like semaglutide (Ozempic\\\/Wegovy) or tirzepatide (Mounjaro\\\/Zepbound) in clinical trials. Status: Not FDA-approved (as of October 2024). It's in Phase 3 trials (e.g., TRIUMPH studies), with potential approval expected in 2026\u20132027. 10 mg Dosage Context Clinical Trial Dosing: Retatrutide is administered\u00a0weekly via subcutaneous injection. The 10 mg dose is a\u00a0high-end maintenance dose\u00a0tested in trials: Phase\\\/Trial Starting Dose Titration Max Dose Weight Loss (at 48\u201372 weeks) Phase 2 (Obesity) 1 mg Gradual increase every 4 weeks 10 mg** or 12 mg Up to\u00a024.2%\u00a0body weight loss (vs. 2.1% placebo) Phase 2 (T2D) 0.5 mg Gradual 10 mg ~17% weight loss + A1C reduction Evidence: Phase 2 results (NEJM, 2023): At 10\u201312 mg, participants lost 17\u201324% body weight over 48 weeks, with improvements in liver fat, cardiometabolic markers (e.g., blood pressure, lipids), and glycemic control. Superior to tirzepatide's ~20% loss in head-to-head potential (Phase 3 ongoing). Side effects: Mostly GI (nausea, vomiting, diarrhea; 50\u201370% incidence, dose-dependent). Rare: gallbladder issues, elevated heart rate. Availability and Warnings Not Commercially Available: No official 10 mg vials\\\/pens exist. \\\"Retatrutide 10 mg\\\" products online are typically\u00a0unregulated research chemicals\u00a0from compounding pharmacies or overseas labs (e.g., China). Purity is unverified\u2014risk of contamination, underdosing, or fakes. Risks of Unofficial Use: Risk Details Evidence Safety No long-term human data; potential for severe GI issues, pancreatitis, or thyroid tumors (GLP-1 class risk). FDA warnings on compounded semaglutide\\\/tirzepatide analogs. Legality Illegal to buy\\\/sell without prescription in most countries (e.g., US Schedule not yet set, but compounding restricted). DEA\\\/FDA crackdowns on GLP-1 knockoffs. Efficacy Variable potency; lab tests show some \\\"retatrutide\\\" as low as 50% pure. Independent testing (e.g., Janoshik Analytics). Recommendation: Do not self-administer. Consult a doctor for supervised trials or approved alternatives (e.g., tirzepatide). Off-label use lacks safety data\u2014monitor via bloodwork if proceeding under medical guidance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/retatrutide-10mg\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/retatrutide-10mg\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/retatrutide-10mg\\\/#primaryimage\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/photo_5051033548038540504_x.jpg\",\"contentUrl\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/photo_5051033548038540504_x.jpg\",\"width\":700,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/retatrutide-10mg\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/europepharmacy.eu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shop\",\"item\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Retatrutide 10MG\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#website\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/\",\"name\":\"European Pharmacy\",\"description\":\"Order Medication &amp; Pills Online\",\"publisher\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/europepharmacy.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#organization\",\"name\":\"European Pharmacy\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg\",\"contentUrl\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg\",\"width\":1254,\"height\":1254,\"caption\":\"European Pharmacy\"},\"image\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Retatrutide 10MG","description":"GLP-1\u00a0(glucagon-like peptide-1): Suppresses appetite and slows gastric emptying.  GIP\u00a0(glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and fat metabolism.  Glucagon: Promotes energy expenditure and liver fat reduction.  It's primarily studied for\u00a0obesity\u00a0and\u00a0type 2 diabetes, showing superior weight loss compared to single- or dual-agonists like semaglutide (Ozempic\/Wegovy) or tirzepatide (Mounjaro\/Zepbound) in clinical trials. Status: Not FDA-approved (as of October 2024). It's in Phase 3 trials (e.g., TRIUMPH studies), with potential approval expected in 2026\u20132027.  10 mg Dosage Context   Clinical Trial Dosing: Retatrutide is administered\u00a0weekly via subcutaneous injection. The 10 mg dose is a\u00a0high-end maintenance dose\u00a0tested in trials:       Phase\/Trial Starting Dose Titration Max Dose Weight Loss (at 48\u201372 weeks)     Phase 2 (Obesity) 1 mg Gradual increase every 4 weeks 10 mg** or 12 mg Up to\u00a024.2%\u00a0body weight loss (vs. 2.1% placebo)   Phase 2 (T2D) 0.5 mg Gradual 10 mg ~17% weight loss + A1C reduction        Evidence:   Phase 2 results (NEJM, 2023): At 10\u201312 mg, participants lost 17\u201324% body weight over 48 weeks, with improvements in liver fat, cardiometabolic markers (e.g., blood pressure, lipids), and glycemic control.  Superior to tirzepatide's ~20% loss in head-to-head potential (Phase 3 ongoing).  Side effects: Mostly GI (nausea, vomiting, diarrhea; 50\u201370% incidence, dose-dependent). Rare: gallbladder issues, elevated heart rate.    Availability and Warnings   Not Commercially Available: No official 10 mg vials\/pens exist. \"Retatrutide 10 mg\" products online are typically\u00a0unregulated research chemicals\u00a0from compounding pharmacies or overseas labs (e.g., China). Purity is unverified\u2014risk of contamination, underdosing, or fakes.  Risks of Unofficial Use:       Risk Details Evidence     Safety No long-term human data; potential for severe GI issues, pancreatitis, or thyroid tumors (GLP-1 class risk). FDA warnings on compounded semaglutide\/tirzepatide analogs.   Legality Illegal to buy\/sell without prescription in most countries (e.g., US Schedule not yet set, but compounding restricted). DEA\/FDA crackdowns on GLP-1 knockoffs.   Efficacy Variable potency; lab tests show some \"retatrutide\" as low as 50% pure. Independent testing (e.g., Janoshik Analytics).      Recommendation: Do not self-administer. Consult a doctor for supervised trials or approved alternatives (e.g., tirzepatide). Off-label use lacks safety data\u2014monitor via bloodwork if proceeding under medical guidance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/europepharmacy.eu\/de\/shop\/retatrutide-10mg\/","og_locale":"de_DE","og_type":"article","og_title":"Retatrutide 10MG","og_description":"GLP-1\u00a0(glucagon-like peptide-1): Suppresses appetite and slows gastric emptying.  GIP\u00a0(glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and fat metabolism.  Glucagon: Promotes energy expenditure and liver fat reduction.  It's primarily studied for\u00a0obesity\u00a0and\u00a0type 2 diabetes, showing superior weight loss compared to single- or dual-agonists like semaglutide (Ozempic\/Wegovy) or tirzepatide (Mounjaro\/Zepbound) in clinical trials. Status: Not FDA-approved (as of October 2024). It's in Phase 3 trials (e.g., TRIUMPH studies), with potential approval expected in 2026\u20132027.  10 mg Dosage Context   Clinical Trial Dosing: Retatrutide is administered\u00a0weekly via subcutaneous injection. The 10 mg dose is a\u00a0high-end maintenance dose\u00a0tested in trials:       Phase\/Trial Starting Dose Titration Max Dose Weight Loss (at 48\u201372 weeks)     Phase 2 (Obesity) 1 mg Gradual increase every 4 weeks 10 mg** or 12 mg Up to\u00a024.2%\u00a0body weight loss (vs. 2.1% placebo)   Phase 2 (T2D) 0.5 mg Gradual 10 mg ~17% weight loss + A1C reduction        Evidence:   Phase 2 results (NEJM, 2023): At 10\u201312 mg, participants lost 17\u201324% body weight over 48 weeks, with improvements in liver fat, cardiometabolic markers (e.g., blood pressure, lipids), and glycemic control.  Superior to tirzepatide's ~20% loss in head-to-head potential (Phase 3 ongoing).  Side effects: Mostly GI (nausea, vomiting, diarrhea; 50\u201370% incidence, dose-dependent). Rare: gallbladder issues, elevated heart rate.    Availability and Warnings   Not Commercially Available: No official 10 mg vials\/pens exist. \"Retatrutide 10 mg\" products online are typically\u00a0unregulated research chemicals\u00a0from compounding pharmacies or overseas labs (e.g., China). Purity is unverified\u2014risk of contamination, underdosing, or fakes.  Risks of Unofficial Use:       Risk Details Evidence     Safety No long-term human data; potential for severe GI issues, pancreatitis, or thyroid tumors (GLP-1 class risk). FDA warnings on compounded semaglutide\/tirzepatide analogs.   Legality Illegal to buy\/sell without prescription in most countries (e.g., US Schedule not yet set, but compounding restricted). DEA\/FDA crackdowns on GLP-1 knockoffs.   Efficacy Variable potency; lab tests show some \"retatrutide\" as low as 50% pure. Independent testing (e.g., Janoshik Analytics).      Recommendation: Do not self-administer. Consult a doctor for supervised trials or approved alternatives (e.g., tirzepatide). Off-label use lacks safety data\u2014monitor via bloodwork if proceeding under medical guidance.","og_url":"https:\/\/europepharmacy.eu\/de\/shop\/retatrutide-10mg\/","og_site_name":"European Pharmacy","article_modified_time":"2026-09-17T09:51:36+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/europepharmacy.eu\/shop\/retatrutide-10mg\/","url":"https:\/\/europepharmacy.eu\/shop\/retatrutide-10mg\/","name":"Retatrutide 10MG","isPartOf":{"@id":"https:\/\/europepharmacy.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/europepharmacy.eu\/shop\/retatrutide-10mg\/#primaryimage"},"image":{"@id":"https:\/\/europepharmacy.eu\/shop\/retatrutide-10mg\/#primaryimage"},"thumbnailUrl":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/photo_5051033548038540504_x.jpg","datePublished":"2026-09-09T13:10:09+00:00","dateModified":"2026-09-17T09:51:36+00:00","description":"GLP-1\u00a0(glucagon-like peptide-1): Suppresses appetite and slows gastric emptying. GIP\u00a0(glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and fat metabolism. Glucagon: Promotes energy expenditure and liver fat reduction. It's primarily studied for\u00a0obesity\u00a0and\u00a0type 2 diabetes, showing superior weight loss compared to single- or dual-agonists like semaglutide (Ozempic\/Wegovy) or tirzepatide (Mounjaro\/Zepbound) in clinical trials. Status: Not FDA-approved (as of October 2024). It's in Phase 3 trials (e.g., TRIUMPH studies), with potential approval expected in 2026\u20132027. 10 mg Dosage Context Clinical Trial Dosing: Retatrutide is administered\u00a0weekly via subcutaneous injection. The 10 mg dose is a\u00a0high-end maintenance dose\u00a0tested in trials: Phase\/Trial Starting Dose Titration Max Dose Weight Loss (at 48\u201372 weeks) Phase 2 (Obesity) 1 mg Gradual increase every 4 weeks 10 mg** or 12 mg Up to\u00a024.2%\u00a0body weight loss (vs. 2.1% placebo) Phase 2 (T2D) 0.5 mg Gradual 10 mg ~17% weight loss + A1C reduction Evidence: Phase 2 results (NEJM, 2023): At 10\u201312 mg, participants lost 17\u201324% body weight over 48 weeks, with improvements in liver fat, cardiometabolic markers (e.g., blood pressure, lipids), and glycemic control. Superior to tirzepatide's ~20% loss in head-to-head potential (Phase 3 ongoing). Side effects: Mostly GI (nausea, vomiting, diarrhea; 50\u201370% incidence, dose-dependent). Rare: gallbladder issues, elevated heart rate. Availability and Warnings Not Commercially Available: No official 10 mg vials\/pens exist. \"Retatrutide 10 mg\" products online are typically\u00a0unregulated research chemicals\u00a0from compounding pharmacies or overseas labs (e.g., China). Purity is unverified\u2014risk of contamination, underdosing, or fakes. Risks of Unofficial Use: Risk Details Evidence Safety No long-term human data; potential for severe GI issues, pancreatitis, or thyroid tumors (GLP-1 class risk). FDA warnings on compounded semaglutide\/tirzepatide analogs. Legality Illegal to buy\/sell without prescription in most countries (e.g., US Schedule not yet set, but compounding restricted). DEA\/FDA crackdowns on GLP-1 knockoffs. Efficacy Variable potency; lab tests show some \"retatrutide\" as low as 50% pure. Independent testing (e.g., Janoshik Analytics). Recommendation: Do not self-administer. Consult a doctor for supervised trials or approved alternatives (e.g., tirzepatide). Off-label use lacks safety data\u2014monitor via bloodwork if proceeding under medical guidance.","breadcrumb":{"@id":"https:\/\/europepharmacy.eu\/shop\/retatrutide-10mg\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/europepharmacy.eu\/shop\/retatrutide-10mg\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/europepharmacy.eu\/shop\/retatrutide-10mg\/#primaryimage","url":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/photo_5051033548038540504_x.jpg","contentUrl":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/photo_5051033548038540504_x.jpg","width":700,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/europepharmacy.eu\/shop\/retatrutide-10mg\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/europepharmacy.eu\/"},{"@type":"ListItem","position":2,"name":"Shop","item":"https:\/\/europepharmacy.eu\/shop\/"},{"@type":"ListItem","position":3,"name":"Retatrutide 10MG"}]},{"@type":"WebSite","@id":"https:\/\/europepharmacy.eu\/#website","url":"https:\/\/europepharmacy.eu\/","name":"European Pharmacy","description":"Order Medication &amp; Pills Online","publisher":{"@id":"https:\/\/europepharmacy.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/europepharmacy.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/europepharmacy.eu\/#organization","name":"European Pharmacy","url":"https:\/\/europepharmacy.eu\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/europepharmacy.eu\/#\/schema\/logo\/image\/","url":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg","contentUrl":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg","width":1254,"height":1254,"caption":"European Pharmacy"},"image":{"@id":"https:\/\/europepharmacy.eu\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/product\/10300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/comments?post=10300"}],"version-history":[{"count":1,"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/product\/10300\/revisions"}],"predecessor-version":[{"id":10363,"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/product\/10300\/revisions\/10363"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/media\/10362"}],"wp:attachment":[{"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/media?parent=10300"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/product_brand?post=10300"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/product_cat?post=10300"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/europepharmacy.eu\/de\/wp-json\/wp\/v2\/product_tag?post=10300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}